Rational development of gemcitabine-based nanoplatform for targeting SERPINB9/Granzyme B axis to overcome chemo-immune-resistance

Haozhe Huang, Yiqing Mu, Yixian Huang, Beihong Ji, Yifei Wang, Chien-Yu Chen, Yuang Chen, Zhangyi Luo, Sihan Li, Ziqian Zhang, Luxuan Wang, James F. Conway, Da Yang, Junmei Wang (), Jingjing Sun () and Song Li ()
Additional contact information
Haozhe Huang: University of Pittsburgh
Yiqing Mu: University of Pittsburgh
Yixian Huang: University of Pittsburgh
Beihong Ji: University of Pittsburgh
Yifei Wang: University of Pittsburgh
Chien-Yu Chen: University of Pittsburgh
Yuang Chen: University of Pittsburgh
Zhangyi Luo: University of Pittsburgh
Sihan Li: University of Pittsburgh
Ziqian Zhang: University of Pittsburgh
Luxuan Wang: University of Pittsburgh
James F. Conway: University of Pittsburgh
Da Yang: University of Pittsburgh
Junmei Wang: University of Pittsburgh
Jingjing Sun: University of Pittsburgh
Song Li: University of Pittsburgh

Nature Communications, 2025, vol. 16, issue 1, 1-19

Abstract: Abstract SERPINB9, an endogenous inhibitor of granzyme B (GzmB), has emerged as a critical factor in the resistance to immunotherapy by protecting cancer cells from GzmB-induced cytotoxicity. However, its role in chemosensitivity remains unknown. In this study, we show that gemcitabine (GEM) treatment upregulates SERPINB9 through transcription factor ATF-3. Interestingly, GEM also induces the expression of GzmB and knockout or knockdown of SERPINB9 results in enhanced response of tumor cells to GEM, suggesting a role of GzmB/SERPINB9 axis in regulating chemosensitivity. To facilitate the therapeutic translation of these findings, we engineer POEM nanocarrier (consisting of lipid-derivatized polylysine (PEG-PLL-Oleic acid, PPO), and GEM-conjugated polylysine (PEG-PLL-OA-GEM, PPOGEM), PPO/PPOGEM (POEM)) that is highly effective in codelivery of built-in GEM and loaded SERPINB9 short interfering RNA (siSPB9). GEM conjugation introduces an additional mechanism of carrier/siRNA interaction in addition to charge-mediated interaction and enables efficient i.v. delivery at lower N/P ratios. Here, we show that co-delivery of GEM and siSPB9 significantly improves antitumor efficacy and remodels the tumor immune microenvironment in pancreatic cancer models, supporting a promising therapeutic strategy.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-59490-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-59490-y

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-59490-y

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().